Proteinea is a TechBio company building a next-generation antibody design engine centered on programmable Fc-domain biology. We engineer novel Fc scaffolds to precisely modulate immune outcomes and unlock product profiles beyond the reach of existing IgG backbones. 

Our scaffolds are engineered for fine-tuned control of receptor engagement, cell-type specificity, biodistribution, and pharmacokinetics. Current focus is on FcγR2b (CD32b) and FcRn biology across autoimmune, rheumatic, and neuroinflammatory conditions. Lead assets incorporate proprietary Fc modifications for:

(1) Selective CD32b agonism to restore immune homeostasis without broad suppression.

(2) FcRn-mediated half-life control, autoantibody clearance, and barrier transport.

We advance internal programs and pursue selective partnerships to apply our Fc domains across multiple therapeutic targets.